← Human Trials & Peer-Reviewed Studies
Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in chronic renal failure
Plain-language guide to PMID 16396628 (2006): placebo-controlled randomized controlled trial study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 13 patients.
Key Facts
- PMID
- 16396628
- Journal
- Clinical science (London, England : 1979)
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Pedersen EB et al. (5 authors)
- DOI
- 10.1042/CS20050336
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide).
The aim of the present study was to test the hypotheses that ANP and BNP are secreted in pulses in dialysis patients, and that pulsatile secretion is regulated by prostaglandins.
Why It Was Studied
Secretion of ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) is pulsatile in healthy humans.
Blood samples were drawn every 2 min through an intravenously inserted plastic needle over a period of 1-2 h in 13 dialysis patients and 13 healthy control subjects (Study 1), and in 15 healthy control subjects, who participated in a randomized placebo-controlled cross-over study after treatment with indomethacin and placebo (Study 2).
Who Took Part
According to the abstract, 13 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, placebo-controlled and crossover study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.
Each person switched between BNP (Nesiritide) and the comparison at some point, usually with a gap in between.
What Was Measured
The subject headings attached to it are Analysis of Variance, Atrial Natriuretic Factor, Case-Control Studies, Cyclooxygenase Inhibitors, Heart Rate, Indomethacin and Kidney Failure, Chronic.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 13 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2006 (Clinical science (London, England : 1979)), a journal based in England.
More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compounds
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.